These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 7579358

  • 1. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism.
    Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martiat P.
    Blood; 1995 Nov 15; 86(10):3891-6. PubMed ID: 7579358
    [Abstract] [Full Text] [Related]

  • 2. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 15; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 3. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides.
    Vaerman JL, Moureau P, Deldime F, Lewalle P, Lammineur C, Morschhauser F, Martiat P.
    Blood; 1997 Jul 01; 90(1):331-9. PubMed ID: 9207469
    [Abstract] [Full Text] [Related]

  • 4. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B.
    Blood; 1996 Aug 01; 88(3):1005-12. PubMed ID: 8704208
    [Abstract] [Full Text] [Related]

  • 5. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B.
    Leukemia; 1997 Jun 01; 11(6):811-9. PubMed ID: 9177433
    [Abstract] [Full Text] [Related]

  • 6. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ.
    Leukemia; 1994 Jan 01; 8(1):129-40. PubMed ID: 8289478
    [Abstract] [Full Text] [Related]

  • 7. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R, Sala R, De Propris MS, Cordone I, de Fabritiis P.
    Leuk Lymphoma; 1999 Nov 01; 35(5-6):471-81. PubMed ID: 10609784
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec 01; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 10. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.
    Blood; 1996 Oct 15; 88(8):3091-100. PubMed ID: 8874208
    [Abstract] [Full Text] [Related]

  • 11. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
    Martiat P, Lewalle P, Taj AS, Philippe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, Michaux JL.
    Blood; 1993 Jan 15; 81(2):502-9. PubMed ID: 8422466
    [Abstract] [Full Text] [Related]

  • 12. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
    Thomas M, Kosciolek B, Wang N, Rowley P.
    Leuk Res; 1994 Jun 15; 18(6):401-8. PubMed ID: 8207957
    [Abstract] [Full Text] [Related]

  • 13. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ.
    Leukemia; 1995 Jan 15; 9(1):118-30. PubMed ID: 7845006
    [Abstract] [Full Text] [Related]

  • 14. The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
    Rowley PT, Keng PC, Kosciolek BA.
    Leuk Res; 1996 Jun 15; 20(6):473-80. PubMed ID: 8709619
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R, Verfaillie CM.
    Blood; 1998 May 01; 91(9):3414-22. PubMed ID: 9558400
    [Abstract] [Full Text] [Related]

  • 16. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B.
    Blood; 1995 Jul 15; 86(2):726-36. PubMed ID: 7606002
    [Abstract] [Full Text] [Related]

  • 17. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P, Amadori S, Calabretta B, Mandelli F.
    Bone Marrow Transplant; 1993 Sep 15; 12(3):261-5. PubMed ID: 8241986
    [Abstract] [Full Text] [Related]

  • 18. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX, Belloc F, Vianes I, Barbot C, Boiron JM, Cowen D, Lacombe F, Brizard A, Bilhou-Nabera C, Bernard P.
    Leuk Lymphoma; 1995 Nov 15; 19(5-6):423-9. PubMed ID: 8590842
    [Abstract] [Full Text] [Related]

  • 19. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.
    Rowley PT, Kosciolek BA, Kool ET.
    Mol Med; 1999 Oct 15; 5(10):693-700. PubMed ID: 10602778
    [Abstract] [Full Text] [Related]

  • 20. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
    O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM.
    Leukemia; 1994 Dec 15; 8(12):2156-62. PubMed ID: 7808004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.